SCHEMBL24257763

SCHEMBL24257763

Cc1ccc(-c2cnc(C#N)c(Cl)c2C)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
PIK3CD O00329 1/20 0.35
PDK2 Q15119 1/20 0.35
HPGDS O60760 1/20 0.34
PTGS2 P35354 7/20 0.34
PTGS1 P23219 2/20 0.34
TDO2 P48775 1/20 0.34
ABCC4 O15439 1/20 0.34
ABCB11 O95342 1/20 0.34
PDE4D Q08499 1/20 0.34
MAPK14 Q16539 1/20 0.34
EED O75530 1/20 0.34
SUZ12 Q15022 1/20 0.34
EZH2 Q15910 1/20 0.34
PDE10A Q9Y233 2/20 0.33
KDM1A O60341 1/20 0.32
HPGD P15428 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546870 1.00 KDM4E (0.35) KDM4EALDH1A1POLBPIK3CDPDK2
SCHEMBL24257695 0.82 KDM4E (0.45) KDM4EALDH1A1HPGDRXFP1
SCHEMBL30453176 0.82 KDM4E (0.45) KDM4EALDH1A1HPGDRXFP1
SCHEMBL30452683 0.82 SLC34A1 (0.40) PDE10A
SCHEMBL24257511 0.82 SLC34A1 (0.40) PDE10A
SCHEMBL24257513 0.80 KDM4E (0.38) KDM4EALDH1A1POLBPTGS2PTGS1
SCHEMBL30453043 0.80 KDM4E (0.38) KDM4EALDH1A1POLBPTGS2PTGS1
SCHEMBL24257719 0.80 CYP1A2 (0.39) KDM4EPOLB
SCHEMBL30453344 0.80 CYP1A2 (0.39) KDM4EPOLB
SCHEMBL24257730 0.77 NPSR1 (0.41) KDM4EALDH1A1POLBHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 KDM4E 175/4885ALDH1A1 1362/4885POLB 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.